Objective: We aimed to perform a standardized review of available mobile health (mHealth) applications (apps) for systemic lupus erythematosus (SLE) and to conduct a systematic review of the literature on mHealth technologies in SLE. Methods: Google Play and AppStore in the United States of America were queried and the quality of eligible mHealth apps was assessed using the Mobile App Rating Scale (MARS). Web of Science, EMBASE, Medline, and Cochrane databases were systematically searched from inception through June 2019. Results: Of 324 mHealth apps found, 20 were eligible for inclusion; 10 focused on education, 7 offered tools to track patient-reported symptoms, 5 included interactive online communities, and 1 enabled emoji sharing. The reviewed apps scored poorly on the MARS quality scale with a mean score 2.3 (0.6) out of 5. Of 1147 studies identified in the literature review, 21 were eligible for inclusion; 11 studies (52.4%) focused on the development and use of mHealth for providing patient information, while only 2 (9.5%) were randomized trials of mHealth interventions. Conclusions: Although there is growing interest in the development of mHealth technologies to support SLE patients, currently available tools are of poor quality and limited functionality, and the literature examining this area is sparse. Lupus (2020) 29, 144-156.
Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease accompanied by substantial physical, psychological, and functional disabilities. 1, 2 SLE is associated with a significant economic burden on individuals and society with estimated direct costs ranging from US$33,000 to more than US$70,000 dollars per patient annually. 1 Current clinical practice guidelines for the management of SLE recommend a combination of pharmacological and non-pharmacological treatment strategies administered by a multidisciplinary team, but treatment options remain limited and poorly tolerated, with frequent toxicities and low medication adherence. 1, [3] [4] [5] Treatment goals include survival, prevention of organ damage and disease flares, and optimization of health-related quality of life. 6, 7 Strategies to improve SLE patient outcomes such as patient education, peer support, and close monitoring of disease activity can reduce the risk of flares and improve quality of life. 7, 8 The use of mobile technologies to support health (mHealth technologies), specifically mHealth applications (apps), has the potential to improve outcomes in SLE by empowering patients through education, symptom tracking, and peer support. [9] [10] [11] mHealth apps can offer numerous functionalities for disease management including home-based exercise programs, symptom trackers, medication diaries, educational information, and movement analysis. 11 These may be particularly powerful tools in SLE which commonly affects young adults, who are typically avid smartphone users familiar with the use of mobile apps. 2, 12, 13 In addition to directly helping patients monitor and manage their health, mHealth apps can facilitate clinical research by enabling investigators to collect patient outcomes more reliably and precisely through remote longitudinal data tracking. 11, 14 As a result, there is significant interest in the development and use of mHealth apps among SLE patients, clinicians, and clinical investigators alike. 10, 15 Understanding the current status of mHealth technologies in SLE, especially the availability and functionality of apps and the literature supporting the use of this technology, is critical to first identifying, and then meeting the needs of this population. To the best of our knowledge, there are no systematic reviews describing mHealth technologies for patients with SLE. Therefore, the aims of this study are: (a) to perform a standardized review of existing mHealth apps for patients with SLE; and (b) to provide a systematic review of the literature on mHealth technologies in SLE. The results of this study will guide the development of more robust patient-centered treatment strategies for SLE and inform the creation of new technological tools to improve data collection methods for clinical trials.
Methods
This review was divided into two parts: (a) systematic review of mHealth apps; and (b) systematic review of the literature. For the mHealth app review, we searched two online app stores in the United States of America (USA): AppStore (Apple Inc) and Google Play (Google Inc). For the literature review, we systematically searched Web of Science, EMBASE, Medline, and Cochrane databases according to PRISMA guidelines (online Supplementary File 1). 16, 17 mHealth apps review
We searched for mHealth apps in the USA Google Play Store (Android) and the AppStore (iOS) using an Android device (Motorola Z4, system version Android 9) and an Apple device (iPhone X, system version 12.4) on 23 July 2019. Google Play and AppStore together account for 99.7% of the USA mobile phone market. 18 The search terms for both stores included keywords normally used in traditional systematic reviews of SLE: ''lupus'' and ''systemic lupus erythematosus.'' No restrictions on app cost were applied.
Apps were included if they were a self-contained product (i.e. did not require add-ons or another type of external device to work). We only included apps in English that were developed or updated in 2017-2019, since updates ensure software functionality and ongoing technical support to the users. We included smartphone apps which were: (a) targeted to SLE, (b) without age restriction, and (c) provided information on at least one of the following recommended strategies for SLE management: education, counseling, or monitoring of patients' health. Apps advertising a specific clinic or product were excluded.
Unclear app descriptions were discussed between LD and SW to determine inclusion. A third reviewer (SK) was available to adjudicate any disagreements. If the same app was available on both platforms (iOS or Android), the iOS version of the app was used for inclusion and analysis. When both paid and free versions of an app were available, only the paid version was reviewed. If the free app offered additional paid functionalities (in-app purchases), the full content of the app was evaluated. A final list of the included apps was created in an Excel spreadsheet (Microsoft Corp), with metadata about each app extracted from the relevant stores. This included information about the developer, price, app size (in megabytes), app version, and a brief summary of the app contents.
The evaluation of app quality was performed using the 23-item Mobile App Rating Scale (MARS). 19 MARS, a validated tool for assessing the quality of apps, is divided into five sections: engagement (five items), functionality (four items), aesthetics (three items), information quality (seven items), and subjective app quality scores (four items). Each of the 23 items is scored using a 5-point scale, with higher scores indicating better quality. An overall mean app quality score was calculated from individual mean scores of engagement, functionality, aesthetics, and information quality. As the subjective quality section of the MARS is optional, it was not included in the analysis in order to strengthen the objectivity of the scale as a measure of app quality. 19 A detailed description of each section of the MARS scale is presented in Table 1 .
Following MARS recommendations, the two primary reviewers (LD and SW) were trained to use the MARS scale by studying training slides provided by the authors of the scale. 19 For further training, 10 randomly selected apps within the health and fitness and medical categories of the iOS AppStore were independently assessed by the two reviewers and their scores were compared to evaluate consensus. Any cases of disagreement (>2-point difference in any of the MARS subscale mean scores) were discussed with a third reviewer (SK). 19 Mobile health technologies in lupus LO Dantas et al.
In addition, the meaning of any MARS items that could be potentially ambiguous was clarified between reviewers. Online user ratings in app stores were not considered in evaluating apps as these can be falsified and may be invalid indicators of app quality. 20 
Literature review
We searched EMBASE, Web of Science, Medline/ PubMed, and the Cochrane databases from their inception through June 2019. No restriction on language or publication year was applied. To maximize the search results, controlled vocabulary was searched using Medical Subject Headings (MeSH). The strategies used are presented in online Supplementary File 2. We used a webbased screening tool to conduct abstract and full text screening of the references gathered from the literature search (http://rheumatology.tuftsmedicalcenter.org/CTCIA). We manually searched the reference lists of the most recent systematic reviews and reviewed the conference proceedings published up until June 2019. Inclusion criteria were original research studies including randomized trials, observational, qualitative and survey-based studies, or review articles related to the development or use of mHealth technologies targeting people of all ages with an SLE diagnosis. The term ''mHealth technology'' was defined as the use of technology for health purposes deployed in a mobile phone, smartphone, tablet, wearable device, or web-related system. Editorials, abstracts, and opinion pieces were excluded.
Two reviewers (LD, MO) independently assessed the title and abstract of each reference to determine potential eligibility. Articles included during this stage were deemed eligible for full text screening. Full manuscripts for eligible abstracts were obtained and examined thoroughly by the same independent reviewers (LD, MO). Any discrepancies during abstract and full text screening were resolved by a third investigator (SK). Quality of the randomized trials were assessed at the study level using the Cochrane risk of bias tool. 17 We used the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies. 21 
Results

mHealth apps review
Of the 324 relevant mHealth apps found by our search, only 19 were eligible for inclusion in the analyses (Figure 1 ). There was one app (ArthritisPower), which was not found through our search, was included in the study as it was known to the authors to have content of relevance to individuals with SLE. A total of 20 mHealth apps were included in the final analysis. The most common reasons for exclusion were duplicates, apps that were not updated, or apps not relevant to the topic of this review. Of the 20 apps included, 1 (5%) was found in the AppStore exclusively, 6 (30%) in Google Play exclusively, and 13 (65%) were found in both Google Play and AppStore. There were three (15%) paid apps, ranging in price from US$0.99 to US$4.99. Only one app offered in-app purchases with three package purchases costing US$0.99 each. The detailed characteristics of the included mHealth apps are described in Table 2 .
Of the 20 apps, 10 offered educational content, 7 offered tools for tracking patient-reported symptoms, 5 offered interactive online communities, and 1 offered emojis to share through text messages or electronic mail for the purpose of entertainment. One app did not provide a login screen when prompted, and therefore could not be fully evaluated. This app was excluded from review with MARS and classified in Table 2 with the available information from the online app stores.
MARS scale
The mean (SD) MARS app quality score for the 19 evaluated apps was 2.3 (0.6) on a 0-5 scale. Most apps scored poorly based on design, user interface, functionality, and credibility. The mean MARS engagement subscale score was 2.5 (0.7); the mean MARS functionality subscale score was 2.9 (0.5), with most apps being functional and easy to use; and the mean MARS aesthetics subscale score was 2.2 (0.5), with apps generally presenting unattractive layouts with low-resolution graphics. The majority of the apps provided low-quality information from questionable sources (i.e. sources were not cited, or their legitimacy was unknown or unverifiable) and received a mean MARS information subscale score of 1.6 (0.4). Of note, there was high agreement between the two reviewers using the MARS scale, with scores never differing by more than the 2-point threshold established for consensus. Table 3 presents the assessment of the quality of the reviewed apps using the MARS scale.
Highest scoring apps for SLE
The three highest scoring apps for SLE received overall mean app quality scores in the range of 3, indicating moderate overall scores. While all three apps focused on tracking patient-reported outcomes, none of them utilized validated outcome measures. In addition, the apps neither offered connectivity with wearable devices nor incorporated methods of passive data collection such as steps count, walking distances, flights climbed, calories expenditure, or sleep monitoring. Two of them (Lupus Corner Health Manager and PatientsLikeMe) provided social network components and interactive support groups. All three apps were interactive and customizable with a reasonable level of content and visual appeal. However, none offered features for patients to create and track goals, directly connect with a physician or expert in the field or synchronize data with electronic health records. None of the apps provided patients with feedback by analyzing data that was collected. This app enables users to track symptoms including pain, fatigue, and ability to plan activities by answering three questions using a 5-level nominal scale.
Users can also answer a general question about how they are doing and log side effects experienced. Other major functionalities include appointment tracking and medication logs/ reminders. In addition, users can engage in a community within the app, where they can post questions and receive feedback from other users through comments. The app also provides updated, but unverified information about SLE formatted in articles.
PatientsLikeMe (overall mean app quality score 3.1)
The main purpose of this app is to create an active community where people can post questions and receive feedback from other users about their health conditions through comments or inbox messages. Users can follow other users and send positive feedback through buttons such as ''like'', ''applause'', and ''support''. Other major functionalities include the ability to post pictures, track moods, and answer a standardized monthly questionnaire created by the app developers about the disease and associated symptoms.
Literature review
Of the 1147 relevant references found in our systematic search, only 21 studies were eligible for inclusion in the final review ( Figure 2 ). The most common reason for exclusion was a focus outside the scope of mHealth. Included studies were published between the years of 2002 and 2018. Of the included studies, 10 (48%) were observational, 4 (19%) were qualitative, 3 (14%) were reviews, 2 (9.5%) were randomized trials, and 2 (9.5%) were study protocols for future randomized trials. 10, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] The detailed characteristics of the included studies are described in Table 4 . Among studies specifying a sample size, the median (range) number of SLE patients included was 84 (1-153). The most common category of papers focused on the development and use of mHealth for providing patient information (development-patient information) and comprised 11 studies (52.4%). The remaining studies described mHealth interventions (23.8%); study protocols (9.5%); and the development of mHealth apps, websites, or mHealth interventions (development-app) (14.3%).
Three studies (14.3%) focused on evaluating the use of web-based systems, two (9.5%) evaluated the use of text messaging, and two (9.5%) examined the use of wearable devices. 23, 32, 33, [36] [37] [38] 41 These studies had mixed results, and due to small sample sizes (ranging from 9 to 41 SLE patients), their interpretability is limited. Some studies explored the development of mHealth technologies, including preferences for patient information and apps. Seven of these studies (33.3%) identified a need for more interactive educational platforms with high-quality information, two (9.5%) demonstrated a need for the development of novel methods of disease monitoring, and two (9.5%) established a need for sources of support such as virtual communities. [24] [25] [26] [27] [28] 30, 32, 34, 35, 39 Randomized Trials using mHealth technologies for SLE The first randomized trial identified in the review compared the effects of cellular text messaging reminders with education on adherence to clinic visits (standard of care) in a cohort of 70 patients Subjects had a significant improvement in medication adherence using the web-based system and even higher improvements if they also had social media support. Empowerment, sense of agency and sense of community appear to play key roles in the possible mechanisms of this improvement. with childhood-onset SLE. Authors demonstrated that the use of text messaging reminders improved visit adherence, but not adherence to hydroxychloroquine. 38 This finding is contrary to established literature showing that text messaging approximately doubles the odds of medication adherence in individuals with chronic diseases. 42 The second trial tested a telephone-based weight management program associated with a web-based health interface that collected information on patient demographics, barriers to physical activity, physical activity participation, nutritional intake, goal setting, and implementation strategies. The interface also provided links to health promotional materials for adults with physical disabilities. 37 The study found a small but significant effect of the intervention in reducing the body mass index of adults with significant physical disabilities, but, notably, only one patient (1.1%) in the study had SLE. The risk of bias distribution and assessment of both trials are presented in online Supplementary Files 3 and 4, respectively. The literature review demonstrated that individuals with SLE seek mHealth tools that promote disease management by including reliable educational information, functionalities to track and communicate symptoms, features to assist with medication adherence, and peer support. 10, 35, 36, 41 However, the majority of the included studies (90.4%) did not focus on evaluating the effectiveness of mHealth interventions in SLE patients. The quality of the observational studies is presented in online Supplementary File 5.
Discussion
To the best of our knowledge, this is the first systematic review evaluating the use of mHealth technologies in SLE. Our study demonstrates that mHealth technologies supporting patients with SLE is an area of significant unmet need. Our review of currently available mHealth apps for SLE demonstrated that the majority of the existing apps scored poorly on the MARS scale and lacked the evidence-based information and functionalities desired by patients such as relevant educational material, symptom and medication trackers, and discussion groups to communicate with experts and peers. Though our systematic literature review found that patients seek to use mHealth technologies to aid with disease management, 10, 36 we identified few studies exploring mHealth-based interventions to improve health outcomes, with the limited published literature devoted to the use of mHealth platforms to provide educational information.
Interpretation of the main findings mHealth apps review
Our review of available mHealth apps for SLE reveals a significant lack of functional, usercentered tools that meet the described needs of SLE patients. Among the included apps, Lupus Corner Health Manager is the only one that addresses the majority of the preferences of SLE patients identified in our literature review. This app provides educational material, a symptom and medication tracker, and a discussion group for communicating with others living with lupus-all key features of mHealth technologies in the management of chronic diseases. 20, 43, 44 However, the majority of the other apps reviewed offered educational information or symptom trackers exclusively, only partially satisfying SLE patients' stated needs. The MARS results revealed low scores for all the apps reviewed, suggesting that major improvements are needed. The information domain scored the lowest, mainly because none of the available apps for SLE provided verifiable information. In addition to providing low-quality educational content, none of the assessed apps used validated patientreported outcome measures to evaluate symptoms, limiting the reliability and external validity of the data collected. The engagement domain scored poorly primarily because the apps did not use specific strategies to entertain users and stimulate repeat use.
Apps that are successful in engaging users in selfmanagement of chronic conditions often incorporate gamification, the use of enjoyable mechanics of video games, in non-video game contexts. 45 Gamification tools such as badges, dashboards, scores, goals and challenges, and social interaction with community members can improve user adherence to mHealth technology. Apps for the management of SLE would benefit from the inclusion of such features, particularly given the chronicity of this condition. In addition, the input of endusers-the people living with SLE-in all stages of the app development process is essential for ensuring engaging design. Focus groups of prospective users can guide content, functionality, and user interface design, increasing the likelihood of sustained use after product development. It is unclear if any of the currently available apps reviewed in this study other than the LupusMinder were developed with the input of patients with SLE.
The assessed SLE apps also lacked several important features available in other chronic disease management apps. Currently available SLE apps do not have useful mHealth capabilities including Bluetooth connectivity to allow pairing with external hardware devices, the option for users to create personalized health goals and upload objective biometric measurements as part of symptom logs, the provision of tailored feedback based on data collected, two-way communication between users and health care providers, and clinical decision support systems for providers to interpret app data collected. 43, 46 The addition of these features should be explored to enrich user experience and enhance app functionality for research and clinical care.
Literature review
Although our review of the literature identified significant patient and provider interest in the use of mHealth technology to enhance the management of SLE, we were surprised to identify only two randomized controlled trials evaluating mHealth interventions in SLE patients. Two other papers identified in the review were study protocols for planned randomized controlled trials evaluating mHealth technologies as a part of an intervention for disease self-management (inclusion of an online message board as part of a broader program) and a physical activity counseling intervention (use of a Fitbit wearable device and web-based application for tracking activity). 22, 33 Overall, our literature review reveals an absence of high-quality studies evaluating the efficacy of mHealth technologies in SLE, with the few published studies suffering from small sample sizes and non-reproducible results. Our findings contrast with the robust evidence supporting the effectiveness of mHealth interventions in improving outcomes in several chronic conditions. [47] [48] [49] [50] Collaboration between clinical researchers and app developers is critical to creating and testing the unique capabilities of mHealth technologies in rigorously designed intervention studies.
This study suggests that the use of mHealth technologies for SLE is still a relatively new and unexplored topic, with much potential for future investigation. Strengths of our study include its rigorous systematic approach that follows well-established reporting guidelines. 16, 17 Investigators underwent structured training in the use of the MARS scale prior to initiation of the study and demonstrated strong agreement. However, due to a lack of direct patient input, we lacked insight into the utility of the reviewed apps for patients living with this condition. Other limitations of the study include the high heterogeneity of the included studies and the small sample sizes, which precluded any kinds of meta-analyses. Although there is a growing need and desire for mHealth technologies to support patients with SLE, the availability of apps designed specifically for SLE and the evidence for their efficacy is still limited. The ideal mHealth app for patients with SLE would incorporate evidence-based educational material, customizable symptom and medication trackers, logs for personalized health goals, and connectivity with external hardware devices to enrich data collection. Additional useful features would include gamification components to engage users, the provision of tailored feedback based on collected data, and secure mechanisms of communication and data access between users and health care providers to facilitate treatment planning and coordination of care. However, currently available tools are of poor quality with limited functionality that fails to fulfill the needs of SLE patients. This study calls for the creation of new user-centered mHealth apps to empower the SLE community. To achieve this unmet need, comprehensive multidisciplinary partnerships between clinical researchers, patients, and app developers are critical.
